Weight‐loss drugs improve outcomes in patients with alcohol use disorder
Use of the glucagon‐like peptide‐1 (GLP‐1) receptor agonist semaglutide was associated with reduced risk of alcohol‐related hospitalization in patients with alcohol use disorder (AUD), a cohort study has found. Both semaglutide and the GLP‐1 receptor agonist liraglutide were associated with lower risk of hospitalization than use of medication treatments for AUD. Study results were published online Nov. 13, 2024, in JAMA Psychiatry .
Publication Details
- Journal
- The Brown University Psychopharmacology Update
- Published
- 2025-01-29
- DOI
- https://doi.org/10.1002/pu.31274
- Primary Topic
- Diet and metabolism studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00